More Accurate, Quicker Diagnoses Possible Via New Elsevier Product
Atlanta, June 1, 2006 – Elsevier, the world-leading scientific, technical, and healthcare publisher, launched Path Consult™, a unique, comprehensive online resource that will enable pathologists to make quicker, more accurate diagnoses.
Path Consult is designed to be used in the workplace as a differential diagnosis tool to provide clinical decision support covering every subspecialty area of general pathology. For the first time, pathologists will be able to conduct a side-by-side comparison of up to three diagnoses at a time, significantly reducing the amount of time spent researching the same information offline.
“Path Consult demonstrates Elsevier’s commitment to customers by delivering a truly innovative tool for the end user. Our agile development process is designed to maximize this value in minimum time,” says Jonathan Clark, Executive Vice President, Technology at Elsevier.
Using its established industry leading references from Mosby, Saunders, and Churchill Livingstone, Elsevier developed Path Consult to include more than 10,000 images for more than 500 conditions at launch, and more than 20,000 images for 1200 diagnoses by Fall of 2006.
Path Consult was developed using an agile development process that closely engaged development partners so Elsevier could quickly bring the product to market with the features pathologists really want. The agile process involves a series of product iterations which are adapted based on feedback.
Elsevier worked with leading pathologists to ensure the quality, accuracy, and usability of the online resource. “A plethora of expertly-obtained digital images and succinct textual content combined with the ability to compare similar histopathologic entities at the touch of a button will make the job of any pathologist easier,” says John D. Cochran, MD, a private practice pathologist in Atlanta, Georgia who worked with Elsevier on the development of the product.
Group practices and institutions can sign up for a free trial by visiting www.pathCONSULTDDX.com.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Phone: + 1314 453 4780